The National Strategic Plan 2009-2012 on HIV and AIDS (NSP) is the result of more than a year of preparatory work, starting with the development of Rwanda's Economic Development and Poverty Reduction Strategy (EDPRS) 2008-2012, which sets out the overarching goals for the response to HIV and AIDS as... well as reaffirming Rwanda's commitment to a multi-sector response. In addition, a wide range of analyses carried out in 2007 and 2008 have helped to ensure that the NSP is based on the most up to date understanding of the epidemic, that the strategies are based on evidence of what works in Rwanda and elsewhere, and that the strengths and weaknesses of the systems and mechanisms for responding to HIV and AIDS are addressed through the NSP.
more
During the implementation of the National Strategic Plan 2009–2012 on HIV and AIDS, Rwanda has continued its progress towards universal access to HIV and AIDS services. The new HIV and AIDS National Strategic Plan July 2013–June 2018 (thereafter referred to as ‘the NSP’) presented here is se...t on pursuing the same objective, with inspiration from the global targets of “zero new HIV infections, zero HIV-related deaths and zero stigma and discrimination due to HIV”.
more
Reporting Period 2010-2011
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Accessed: 08.10.2019
Handout presentations in PDF for illustrating lectures
Accessed May 2014
MMWR: Recommendations and Reports / Vol. 62 / No. 9
Morbidity and Mortality Weekly Report
October 25, 2013
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
Division of Tuberculosis Elimination.
The Lancet DOI: 10.1016/S2468-2667(20)30101-8
WHO declared COVID-19 to be a pandemic on March 11, 2020. The pandemic eventually reached Yemen, with the first laboratory confirmed case announced on April 10. emen has structural vulnerabilities that have developed over a protracted period of conflic...t and poor governance, and its health system has suffered the most. To prevent a total collapse of Yemen’s fragile health system, the government and the international community should act now more decisively.
more
The reports bring together the latest findings and conclusions about the state of resistance to artemisinins and artemisinin-based combination therapy (ACT), summarize WHO’s current policy and treatment recommendations, and highlight areas of concern.
5 Nov. 2020
The policy brief provides a concise summary of information and considerations to ensure optimal management of influenza during the COVID-19 pandemic. It includes a list of technical guidance and other resources to assist policy makers with monitoring the situation, preventing seasonal i...nfluenza, reducing severe complications and mortality, protecting specific populations and communicating to and engaging with the public.
more
WHO has a unique combination of technical public health and scientific expertise, and a global operational footprint, with field offices in more than 150 countries. In 2020, this global, technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVI...D-19 public health response, from surveillance and laboratory testing to maintaining essential health services in the most vulnerable and fragile contexts.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.